11 May 2022 | News
The new data build upon previously reported Phase III trial results demonstrating that a rapid reduction of viral load prevents progression to infection after COVID-19 exposure
image credit- businesswire
Canada-based SaNOtize Research and Development has announced results from a retrospective clinical study assessing the efficacy of nitric oxide releasing nasal spray (NONS) in preventing COVID-19 infection after high-risk exposure.
Nitric oxide is a naturally occurring molecule known to have antimicrobial properties, including a direct effect on SARS-CoV-2 and its variants, the virus that causes COVID-19.
The new study, conducted at Srinakharinwirot University in Bangkok, Thailand, found participants who took NONS after COVID-19 exposure were 75% less likely to become infected when compared to the control group, yielding a statistically significant reduction in infection rate.
“The results of this study using real-world evidence suggest NONS is an effective self-administered tool to prevent COVID-19 infection, even after high-risk exposure,” said lead author Jarinratn Sirirattawan, MD, Assistant Professor, Srinakharinwirot University, Ongkharak site, Thailand. “In previous randomized controlled, Phase III, clinical trials, NONS was also shown to be effective in rapidly reducing the duration of disease by 50% in participants who had already acquired COVID-19, suggesting it is a promising tool for both treatment and prevention.”
NONS is not yet approved for sale in Canada or USA. It is approved as a medical device under the brand name VirX in Thailand and as a medical device under the brand name of enovid in Indonesia, Israel, and Bahrain. In India, NONS received an emergency use approval by the Central Drugs Standard Control Organization (CDSCO) for treatment of adult patients with COVID-19 who have a risk of progression of the disease. In Singapore and Nepal, it is registered as a Class I medical device and under CE mark in the European Union.